Concepedia

EGFR overexpression is not common in patients with head and neck cancer. Cell lines are not representative for the clinical situation in this indication

Sami S. Khaznadar, Martin Khan, Elke Schmid, Sebastian Gebhart, Eva-Tessina Becker, Thomas Krahn, Oliver von Ahsen

Oncotarget · 2018 · 20 citations · 37 references

DOIFull text

Open access

Abstract

Cell lines are not representative of the clinical situation in HNSCC. Larger studies should investigate whether patient subgroups with activating EGFR mutations or overexpression can be identified.

References

37

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.4K citations

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

James A. Bonner, Paul M. Harari, J. Giralt et al. · New England Journal of Medicine · 2006 · 5.1K citations · Full text

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

Jan B. Vermorken, Fernando Rivera, Éva Remenár et al. · New England Journal of Medicine · 2008 · 3.7K citations · Full text

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

Richard M. Neve, Koei Chin, Jane Fridlyand et al. · Cancer Cell · 2006 · 3.2K citations · Full text

, , +12